WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009067182) PHOSPHOLIPID COMPOSITIONS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/067182    International Application No.:    PCT/US2008/012846
Publication Date: 28.05.2009 International Filing Date: 17.11.2008
IPC:
A61K 31/661 (2006.01), A61P 3/10 (2006.01), A61P 3/04 (2006.01), A61K 31/685 (2006.01), A61K 31/739 (2006.01), A61K 31/14 (2006.01)
Applicants: BAYLOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, Houston, TX 77030-3411 (US) (For All Designated States Except US).
MOORE, David, D. [US/US]; (US) (For US Only).
LEE, Jae, Man [KR/US]; (US) (For US Only)
Inventors: MOORE, David, D.; (US).
LEE, Jae, Man; (US)
Agent: ELBING, Karen, L.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US)
Priority Data:
60/988,505 16.11.2007 US
Title (EN) PHOSPHOLIPID COMPOSITIONS AND USES THEREOF
(FR) COMPOSITIONS DE PHOSPHOLIPIDES ET LEURS UTILISATIONS
Abstract: front page image
(EN)We have discovered that phospholipids diundecanoyl (C1 1:0-C1 1:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids and structurally related lipids. Also featured are methods of treating metabolic disorders and inflammatory bowel disease, lowering blood glucose levels, and increasing LRH-1 receptor activity in a subject by administration of these lipids.
(FR)Nous avons découvert que les phospholipides diundécanoyl (C1 1:0-C1 1:0) et dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) agissent tels des agonistes du récepteur LRH-1. Nous avons également montré que l'administration de ces lipides à des souris diabétiques réduit les taux de glucose dans le sang. Sur la base de ces découvertes, la présente invention porte sur des compositions qui comprennent ces lipides et des lipides de structure associée. L'invention porte également sur des procédés de traitement de troubles métaboliques et de l'infection abdominale inflammatoire, de diminution des taux de glucose dans le sang et d'augmentation de l'activité du récepteur LRH-1 chez un sujet par l'administration de ces lipides.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)